REN and type 2 diabetes mellitus: Ito et al. conducted a clinical study in which esaxerenone was added to the treatment of 56 patients with type 2 diabetes and UACR ≥ 300 mg/g who were taking a RAS (renin–angiotensin system) inhibitor.